Amphastar Pharmaceuticals, Inc. - Q1 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three-month period ended March 31, 2026. Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredients (APIs). The company operates as a single reportable segment: pharmaceutical products.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenues | $171.2 million | $170.5 million |
| Gross Profit | $70.3 million | $85.3 million |
| Gross Margin | 41.1% | 50.0% |
| Net Income | $6.4 million | $25.3 million |
| Diluted EPS | $0.14 | $0.51 |
| Operating Cash Flow | $47.8 million | $35.1 million |
| Cash & Equivalents (End of Period) | $171.2 million | $183.0 million |
| Total Debt (Gross) | $620.3 million | $619.9 million |
Material Changes vs. Prior Period
- Revenue Stability: Net revenues remained flat year-over-year (+0.4%), driven by a 34% increase in "Other products" (including new launches of albuterol, iron sucrose, and teriparatide) and a 3% increase in epinephrine sales. These gains were offset by significant declines in BAQSIMI® (-15%) and Glucagon (-56%) due to pricing pressures, competition, and shifts to ready-to-use formulations.
- Margin Compression: Gross margin decreased from 50.0% to 41.1%. This was primarily caused by lower average selling prices on high-margin products (BAQSIMI®, glucagon) and increased manufacturing expenses related to facility expansion in Rancho Cucamonga, CA.
- Expense Growth: Operating expenses increased by 18% to $56.7 million. Research and Development (R&D) expenses rose 33% to $26.7 million, driven by pipeline development and a $2.0 million upfront payment for a new licensing agreement. General and Administrative (G&A) expenses increased 13% due to legal fees and ERP system implementation.
- Profitability Decline: Net income dropped 75% to $6.4 million, reflecting the margin compression and increased operating expenses.
Guidance, Outlook, and Risks
- Product Launches: The company launched Ipratropium Bromide HFA inhalation aerosol in April 2026 following FDA approval in February 2026.
- Strategic Agreements: In January 2026, Amphastar entered into a license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for a synthetic corticotropin analog (AMP-110), making a $2.0 million upfront payment. The company also expanded distribution agreements for Primatene MIST® and BAQSIMI® in the Greater China region.
- Capital Allocation: The Board authorized a $50.0 million increase to the share buyback program in March 2026. During Q1, the company repurchased approximately 1.37 million shares for $29.5 million.
- Regulatory Risks: The FDA classified the South El Monte, CA facility as "Official Action Indicated" in April 2026 following a December 2025 inspection. Management has initiated corrective actions and does not anticipate material operational interruptions.
- Contingent Liabilities: The company has potential milestone payment obligations of up to $1.1 billion related to various agreements, including the BAQSIMI® acquisition and new licensing deals.
Investor Verification Checklist
- BAQSIMI® Pricing Dynamics: Verify the sustainability of the 15% revenue decline in BAQSIMI® and the impact of gross-to-net discounts on future margins.
- Glucagon Market Shift: Assess the long-term revenue trajectory of the Glucagon product line given the 56% decline and competitive shift to ready-to-use products.
- Regulatory Compliance: Monitor the status of the South El Monte facility's "Official Action Indicated" classification and the effectiveness of corrective actions.
- R&D Pipeline Progress: Track the development milestones for the new AMP-110 corticotropin candidate and biosimilar insulin programs to justify the 33% increase in R&D spend.
- Related Party Transactions: Review the terms and financial impact of the new licensing and distribution agreements with Hanxin and its subsidiaries.